Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

2008 ◽  
Vol 35 (10) ◽  
pp. 1796-1802 ◽  
Author(s):  
Margarida Rodrigues ◽  
Michael Gabriel ◽  
Dirk Heute ◽  
Daniel Putzer ◽  
Andrea Griesmacher ◽  
...  
Keyword(s):  
Chromogranin A ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours

2015 ◽  
Vol 36 (3) ◽  
pp. 251-259 ◽  
Author(s):  
Aurora Sainz-Esteban ◽  
Roberto Olmos ◽  
Manuel González-Sagrado ◽  
María Luisa González ◽  
María Ángeles Ruiz ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Ct Imaging ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

scholarly journals Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

2006 ◽  
Vol 13 (4) ◽  
pp. 1203-1211 ◽  
Author(s):  
Martin Gotthardt ◽  
Martin P Béhé ◽  
Julia Grass ◽  
Artur Bauhofer ◽  
Anja Rinke ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Added Value ◽  
Imaging Method ◽  
Gastrin Receptor ◽  
Additional Information ◽  
Receptor Scintigraphy ◽  
Better Than

Gastrin receptor scintigraphy (GRS) is a new imaging method primarily developed for the detection of metastases of medullary thyroid carcinoma (MTC). As gastrin-binding CCK2 receptors are also expressed on a variety of other neuroendocrine tumours (NET), we compared GRS to somatostatin receptor scintigraphy (SRS) in patients with NET. SRS and GRS were performed within 21 days in a series of 60 consecutive patients with NET. GRS was directly compared with SRS. If lesions were visible on GRS but not detectable by SRS, other imaging modalities (MRI, CT) and follow-up were used for verification. Of the 60 evaluable patients, 51 had carcinoid tumours, 3 gastrinomas, 2 glucagonomas, 1 insulinoma and 3 paragangliomas. The overall tumour-detection rate was 73.7% for GRS and 82.1% for SRS. In the 11 patients with negative SRS, GRS was positive in 6 (54.5%). Based on the number of tumour sites detected and the degree of uptake, GRS performed better than SRS in 13 patients (21.7%), equivalent images were obtained in 18 cases (30.0%) and SRS performed better in 24 (40.0%) cases. In six of the SRS positive patients, 18 additional sites of tumour involvement could be detected. Overall, GRS detected additional tumour sites in 20% of the patients. Localisation of the primary tumours or their functional status had no influence on the outcome of imaging. GRS should be performed in selected patients as it may provide additional information in patients with NET with equivocal or absent somatostatin uptake.

Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors

2008 ◽  
Vol 22 (4) ◽  
pp. 237-243 ◽  
Author(s):  
Sirianong Namwongprom ◽  
Franklin C. Wong ◽  
Ukihide Tateishi ◽  
Edmund E. Kim ◽  
Sombut Boonyaprapa
Keyword(s):  
Chromogranin A ◽  
Somatostatin Receptor ◽  
Carcinoid Tumors ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours

2004 ◽  
Vol 25 (5) ◽  
pp. 445-449 ◽  
Author(s):  
Giordano Savelli ◽  
Giovanni Lucignani ◽  
Ettore Seregni ◽  
Alfonso Marchian?? ◽  
Gianluca Serafini ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy

scholarly journals Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease

1996 ◽  
Vol 93 (1) ◽  
pp. 96-103 ◽  
Author(s):  
P. J. van den Anker-Lugtenburg ◽  
E. P. Krenning ◽  
H. Y. Oei ◽  
M. P. Van Hagen ◽  
C. J. H. Gerrits ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Somatostatin Receptor ◽  
Somatostatin Receptor Scintigraphy ◽  
Receptor Scintigraphy ◽  
Initial Staging
Sign in / Sign up

Export Citation Format

Share Document